Christopher L. Marsh

Association of Noninvasive Rejection Biomarkers with 10-year Kidney Allograft Survival

James N. Fleming, David Taber, Raymond L. Heilman, Emilio Poggio et autres

KEY POINTS: There is an independent association between two independent noninvasive biomarkers and all-cause graft loss. Time-varying analysis demonstrated that the independent noninvasive biomarkers can provide more information than either one alone. BACKGROUND: The primary objective of this analysis was to assess …

us, fr (code pays fourni par la source)

Biopsy and Blood Gene Expression Distinguish Injury, Subclinical and Clinical Rejection in Kidney Transplant Recipients

Sunil M. Kurian, Christabel Rebello, Sook Hyeon Park, Raymond L. Heilman et autres

Background: Long-term outcomes in kidney transplantation remain suboptimal, with subclinical acute rejection (subAR) frequently going undetected by conventional methods. We hypothesized that subAR represents a molecular precursor to clinical acute rejection (cAR). Leveraging a large National Institutes of Health-funded cohort with matched …

us (code pays fourni par la source)

Development and Evaluation of a New Liver Donor Risk Index

Sunil M. Kurian, D. Janarthanan, Aparna Krishnan, P. Balasubramanian et autres

us (code pays fourni par la source)

Association of Gene Expression Profile with 10-Year All Cause Graft Loss in a Multicenter Prospective Cohort

Christopher L. Marsh, Sunil M. Kurian, James N. Fleming, Lihui Zhao et autres

Purpose: KTx is the treatment of choice for ESKD, but long-term outcomes remain suboptimal. A previous multicenter analysis identified multiple positive GEP tests as associated with graft loss up to 4 years post-transplant, but the sample size was too small for adjustment …

us, fr (code pays fourni par la source)

Machine Learning-Based Cytokine Profiling for Predicting Early Allograft Dysfunction in Transplant Patients

Sunil M. Kurian, Abhishek Krishnan, Allison Martin, Earle F. Burgess et autres

Purpose: Early allograft dysfunction (EAD) is a major complication after liver transplantation with an incidence rangingfrom 5-40%. Cytokine profiling may provide insights into its prediction and prevention. We aimed to build a classifier to identify cytokine profiles associated with EAD using machine …

us (code pays fourni par la source)

Revolutionizing deceased donor transplantation: How new approaches to machine perfusion broadens the horizon for organ donation

Stephanie Almeida, William H. Snyder, Mita M. Shah, Jonathan S. Fisher et autres

Solid organ transplantation is lifesaving for persons with end-stage organ disease. Thanks to advancements in organ preservation, surgeons are now able to successfully transplant organs that were previously considered high risk for poor graft function. Innovations in perfusion machine types, preservation solutions …

us (code pays fourni par la source)

A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy.

Dan P. Zandberg, Jie Chen, Curtis Tatsuoka, Daniel P. Normolle et autres

us (code pays fourni par la source)

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial

Jennifer L. Steel, Charles J. George, Lauren Terhorst, Jonathan G. Yabes et autres

us (code pays fourni par la source)

Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile

Jacob New, Jason Cham, Lana Smith, Leah Puglisi et autres

BACKGROUND: Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging. METHODS: An observational cohort study from December 11, 2020 to September 22, 2022, within a large …

us (code pays fourni par la source)

Doing more with less: the advantages of point-of-care intervention in ascites treatment

Tara Al-Rubyee, Christopher L. Marsh, Biju Thomas

gb (code pays fourni par la source)

Does fit reduce the yield of low- to intermediate-risk polyps?

Tara Al-Rubyee, Christopher L. Marsh, Ravivarma Balasubramaniam, Ingrid Britton

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

Khvaramze Shaverdashvili, Vincent Reyes, Hong Wang, Dhaval Mehta et autres

Background: Approximately 30-40% of patients with advanced and metastatic non-small cell lung cancer (NSCLC) present with an impaired performance status (PS). There are limited prospective data on the safety and efficacy of durvalumab in these patients. Methods: In this single-arm phase II …

us (code pays fourni par la source)